Home/Pipeline/Platform Partnerships (e.g., with Merck)

Platform Partnerships (e.g., with Merck)

Various Infectious Diseases

Pre-clinical/Phase 1Active

Key Facts

Indication

Various Infectious Diseases

Phase

Pre-clinical/Phase 1

Status

Active

Company

Vaxxas

About Vaxxas

Vaxxas is a private, clinical-stage biotech founded in 2011, pioneering a needle-free vaccine delivery platform. Its core technology, the HD-MAP patch, uses thousands of micro-projections to deliver vaccine to the skin, aiming to improve immune response, enable thermostable formulations, and simplify administration. The company has validated its platform in human studies, secured significant partnerships with entities like Merck, BARDA, and CEPI, and is advancing a pipeline focused on influenza and other vaccines towards commercialization.

View full company profile

Therapeutic Areas

Infectious Disease Oncology

Other Various Infectious Diseases Drugs

Drug	Company	Phase	Status
Hyperimmune Globulins	Kedrion Biopharma	Development	Active
Infectious Disease Serology Portfolio Expansion	GenBio	Commercial/Development	Active
Client Projects (Vaccines)	IDT Biologika	Preclinical through Commercial	Active
Partnership-based Vaccine Development & Manufacturing	Bilthoven Biologicals	Varies by Partner	Active
Infectious Disease Assay Development	CD Diagnostics	Development/Validation	Active